

Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation


Kohei Hosokawa,¹ Takamasa Katagiri,^{1,2} Naomi Sugimori,¹ Ken Ishiyama,^{1,3} Yumi Sasaki,¹ Yu Seiki,¹ Aiko Sato-Otsubo,⁴ Masashi Sanada,⁴ Seishi Ogawa,⁴ and Shinji Nakao¹

¹Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Kanazawa; ²Clinical Laboratory Science, Kanazawa University Graduate School of Medical Science, Kanazawa; ³Tokyo Metropolitan Ohtsuka Hospital, Department of Internal Medicine, Toshima; and ⁴Cancer Genomics Project, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

Citation: Hosokawa K, Katagiri T, Sugimori N, Ishiyama K, Sasaki Y, Seiki Y, Sato-Otsubo A, Sanada M, Ogawa S, and Nakao S. Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation. *Haematologica* 2012;97(12):1845-1849. doi:10.3324/haematol.2011.061127

Online Supplementary Table S1. Antibodies used in flow cytometry.

Surface antigen	Isotype	Fluorescein	Source
CD55	IgG2a	FITC	BD Pharmingen
CD59	IgG2a	FITC	Beckman Coulter
CD11b	IgG1	PE	BD Pharmingen
glycophorin A	IgG1	PE	Dako



Online Supplementary Figure S1. Eight patients (UPN1,3,4,8,12,14,15,22) were treated with IST and changes in the proportion of del(13q) cells were available. The percentage of del(13q) clones revealed by G-banding increased in 5 patients (UPN1,3,8(FISH),12,22) and decreased in 3 (UPN4,14,15) after successful IST.